Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 381.2% | -29.3% | -4.7% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 97.7% | 95.5% | 96.8% | 96.5% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | -€0 | -€0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -71% | -766.3% | -394.4% | -159.7% |
| Other Income/Exp. Net | €0 | €0 | -€0 | -€0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | -€0 | -€0 | €0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -63.2% | -736.9% | -403.5% | -374% |
| EPS | -0.22 | -0.55 | -0.44 | -0.45 |
| % Growth | 60% | -25% | 2.2% | – |
| EPS Diluted | -0.22 | -0.55 | -0.44 | -0.45 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -48.3% | -717.8% | -387.4% | -348.2% |